Biotechnology

Bakhu Holdings Appoints Two Independent Directors to Its Board

August 17, 2022 9:11 AM

LONG BEACH, CA / ACCESSWIRE / August 17, 2022 / Bakhu Holdings, Corp. (OTC PINK:BKUH) today announced the addition of two independent members to Board of Directors: Tom Vaknin, 33, and Moshe Morgenstern, 44. Tom Vaknin (left) and Moshe Morgenstern (right) Bakhu Holdings has the exclusive North American rights to this process to grow select cannabinoids in proprietary bioreactors with consistent qualitative and quantitative attributes at what...

Read more

Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call

August 17, 2022 8:01 AM

~ Call to be Held Today, August 17, 2022 at 11am ET ~ SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today released an updated investor presentation to its investor relations website accessible via...

Read more

ITOCO Enters Into JV With Large Nopal Cactus Producer in Portugal

August 17, 2022 7:10 AM

TORONTO, ON / ACCESSWIRE / August 17, 2022 / ITOCO INC. (OTC:ITMC) is pleased to announce it has entered into a Joint Venture (JV) with Diálogos do Bosque, Unipessoal Lda, a large Nopal cactus farm and processing company in Alentejo-Cortiçadas de Lavre, Portugal (approximately 100 kilometers east of the capital Lisbon). The JV was facilitated through ITOCO's Portuguese subsidiary Colorful Euphoria Lda. Nuno Pires, Principal of Diálogos do Bosque...

Read more

BrainChip Empowers Next Generation of Technology Innovators with Launch of the University AI Accelerator Program

August 16, 2022 5:30 PM

LAGUNA HILLS, CA / ACCESSWIRE / August 16, 2022 / BrainChip Holdings Ltd (ASX:BRN) (OTCQX:BRCHF) (ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, is bringing its neuromorphic technology into higher education institutions via the BrainChip University AI Accelerator Program, which shares technical knowledge, promotes leading-edge discoveries and positions students to be next-generation technology innovators. BrainChip's...

Read more

Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update

August 16, 2022 4:10 PM

Conference Call Scheduled for Thursday August 18 at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / August 16, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a...

Read more

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

August 16, 2022 8:05 AM

IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic. Mr. Belteau joined Medtronic as a field engineer upon...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 15, 2022 4:05 PM

Dermata completes a $5.0 million private placement financing in April 2022 DMT310 Phase 2 rosacea trial topline results expected in the second half of 2022 SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress and reported...

Read more

Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics for Ocular Aging Disease Research

August 15, 2022 3:00 PM

LAFAYETTE, NY / ACCESSWIRE / August 15, 2022 / Ichor Life Sciences, a preclinical contract research organization, today announced a $1.5 million investment in MitoChem Therapeutics. Based in Charleston, South Carolina, MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction-a hallmark of aging-in neurodegenerative diseases. MitoChem Therapeutics and Ichor Life Sciences will work together to advance the...

Read more

Biovica invites to market update on 18 August 15.00 - Bringing DiviTum(R)TKa to US patients

August 15, 2022 9:10 AM

UPPSALA, SE / ACCESSWIRE / August 15, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa's US market approval received on July 29 from the US Food and Drug Administration (FDA). At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander will give a short introduction. Joakim Arwidsson, VP RA/QA, about the 510(k) clearance, Henrik...

Read more

EV Biologics Launches Excyte with $100 million Valuation

August 15, 2022 9:00 AM

TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation. Excyte has already raised $500,000 of its $2.5 million initial capitalization goal. This funding will initially provide scale-down biomanufacturing process development and important bioanalytical data to advance EV Biologics' ongoing nanotherapeutic development....

Read more

Vaso Corporation Announces Financial Results for Second Quarter 2022

August 15, 2022 9:00 AM

Company reports net income of $1.5 million on significant revenue growth PLAINVIEW, NY / ACCESSWIRE / August 15, 2022 / Vaso Corporation ("Vaso") (OTC PINK:VASO) today reported its operating results for the three months ended June 30, 2022. "For the second quarter of 2022, the Company recorded a total revenue of $19.5 million, representing a 21% increase year-over-year. As a result, net income improved substantially, to $1.5 million from a net...

Read more

Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022

August 15, 2022 8:00 AM

NEW YORK, NY / ACCESSWIRE / August 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended June 30, 2022. Highlights include: Reported Net Sales for Q2 of $4.2 million Achieved first positive quarter of Adjusted EBITDA over $200,000 Announced positive results of over-the-counter (OTC) label comprehension...

Read more

Black Bird Biotech Management Affirms Long-Term Commitment, Exchanges One-Third, over 120 Million, of Outstanding Common Shares for Preferred Shares

August 15, 2022 8:00 AM

FLOWER MOUND, TX / ACCESSWIRE / August 15, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced that the members of its Board of Directors have agreed to exchange a total of nearly 124 million shares, or approximately 36%, of the Company's outstanding common stock for shares of a new Series A Preferred Stock. All of the transactions are expected to be completed by...

Read more

Hemogenyx Pharmaceuticals PLC Announces Approval and Issuance of Antibody Patent

August 15, 2022 2:00 AM

Approval and Issuance of Chinese Bi-specific Antibody Patent LONDON, UK / ACCESSWIRE / August 15, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that China National Intellectual Property Administration has issued a Notification to Grant Patent Right for the patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM...

Read more

Core One Labs' Subsidiaries Successfully Produce Psilocin Precursor for Production to Psilocybin

August 12, 2022 7:55 PM

VANCOUVER, BC / ACCESSWIRE / August 12, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. ("Awakened") have successfully produced a precursor that can be efficiently converted into psilocin, the psychoactive ingredient of psilocybin, with further conversion into commercially viable...

Read more

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

August 12, 2022 4:30 PM

Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2022 and provided an update on its business. During...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

August 12, 2022 8:00 AM

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic Advancing lead DNase program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the quarter with $14.9 million of cash to fund operations and drive expanded pipeline development forward FRAMINGHAM, MA / ACCESSWIRE / August 12,...

Read more

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

August 11, 2022 4:10 PM

Corporate Update Call to be Held Wednesday, August 17, 2022 SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the second quarter 2022. Dr. Lynn Kirkpatrick, Chief...

Read more

Lexaria Discusses Valuation Metrics for Biotech Industry

August 11, 2022 9:15 AM

Third Party Analysis for Biotech and Pharma Industries KELOWNA, BC / ACCESSWIRE / August 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following information to its stakeholders as an aid to conveniently researching and understanding various non-affiliated third-party sources and their methodologies for valuing biotech and...

Read more

NovAccess Global Announces Uplisting to OTCQB

August 10, 2022 9:00 AM

CLEVELAND, OH / ACCESSWIRE / August 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that the trading of its common shares has been upgraded to the OTC Markets Group's OTCQB® platform from the OTC Pink Market. The Company's ticker symbol remains the same. The OTCQB listing required the completion and submission of financial reporting with the Securities...

Read more